Evenity (Romosozumab) Side Effects, Withdrawal, and Discontinuation Syndrome

What Is Romosozumab and Why Does Discontinuation Matter?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers and decreases bone resorption markers, a dual mechanism unique among approved osteoporosis therapies. [1]

The FDA approved it in April 2019 under the brand name Evenity, specifically for postmenopausal women with osteoporosis at high risk of fracture, defined as a prior osteoporotic fracture or very low T-scores. [2]

Why the 12-Month Limit Is Clinically Significant

The approved regimen is exactly 12 monthly injections. This is not an arbitrary cutoff. By month 12, the anabolic bone-formation signal attenuates substantially, and continuing beyond one year adds little benefit while extending cardiovascular exposure. [3] Stopping at month 12 is therefore predictable and planned, not an abrupt withdrawal in the traditional pharmacologic sense.

Stopping without immediately starting a follow-on antiresorptive drug results in measurable, rapid bone mineral density (BMD) loss. That loss constitutes the primary "discontinuation syndrome" concern with romosozumab, and it differs mechanistically from withdrawal syndromes seen with CNS drugs or corticosteroids.

Regulatory Sequencing Requirement

The Evenity U.S. Prescribing information states directly: "Following Evenity, patients should be transitioned to antiresorptive therapy to maintain bone mineral density gains." [2] Failure to follow this sequencing is the single most common prescribing error identified in post-market safety reviews and pharmacovigilance literature.

Boxed Warning: Cardiovascular Risk

The most serious adverse effect associated with romosozumab is an elevated risk of myocardial infarction (MI), stroke, and cardiovascular death. This risk is serious enough to carry an FDA boxed warning, the strongest safety label available.

The ARCH Trial: The Primary Evidence

The ARCH trial (N=4,093) compared 12 months of romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture. Romosozumab reduced the risk of new vertebral fracture by 48% and clinical fracture by 27% compared with alendronate. [3]

However, the romosozumab group experienced significantly more major adverse cardiovascular events: 2.5% vs. 1.9% in the alendronate arm, a hazard ratio of 1.87 (95% CI 1.13 to 3.08, P<0.05). [3] This was not a pre-specified primary endpoint, but the signal was consistent and drove the boxed warning.

Contrast With the FRAME Trial

The FRAME trial (N=7,180) compared romosozumab to placebo and did not detect a statistically significant cardiovascular difference. [4] The cardiovascular excess in ARCH specifically emerged in active comparison against alendronate, a drug that may itself carry a cardioprotective signal. The true magnitude of romosozumab's intrinsic cardiovascular risk therefore remains debated in the literature.

Clinical Screening Before Prescribing

The FDA label and the American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines both recommend against initiating romosozumab in patients who have experienced an MI or stroke within the preceding 12 months. [2][5] For patients with multiple cardiovascular risk factors, a risk-benefit discussion is mandatory before the first injection.

Injection-Site Reactions

Injection-site reactions are the most frequently reported adverse events in clinical trials. In pooled FRAME and ARCH data, injection-site pain, erythema, and swelling occurred in approximately 10.5% of romosozumab-treated patients vs. 7.0% of placebo-treated patients. [4]

Characteristics and Management

Most reactions are mild to moderate, self-limiting, and peak within 24 to 48 hours of the injection. Rotating the injection site among the abdomen, upper arm, and thigh reduces local tissue accumulation. Applying a cold compress for 5 minutes before the injection and allowing the prefilled syringe to reach room temperature for at least 30 minutes before administration reduces discomfort. Systemic hypersensitivity reactions, including urticaria and angioedema, have been reported rarely and are captured in the FAERS database, but anaphylaxis has not been confirmed in controlled trial data.

Hypocalcemia

Romosozumab rapidly increases bone formation, which draws calcium into mineralizing bone matrix. In patients who are already vitamin D deficient or hypocalcemic, this can precipitate symptomatic hypocalcemia.

Pre-treatment serum calcium and 25-hydroxyvitamin D levels should be measured in all patients. The label requires correction of hypocalcemia before the first dose. [2] Patients with severe renal impairment (CrCl <30 mL/min) or who are on dialysis are at highest risk and require more frequent calcium monitoring during the treatment course.

Osteonecrosis of the Jaw (ONJ)

ONJ, defined as exposed or necrotic bone in the jaw persisting for more than eight weeks, is a rare but serious adverse event associated with antiresorptive and anabolic bone agents. Cases have been reported with romosozumab in both clinical trials and post-market surveillance.

Reported Incidence and Risk Factors

In controlled trials, ONJ was reported in 0.04% of romosozumab-treated patients. [2] Risk factors follow the same pattern established for bisphosphonates and denosumab: dental extractions, dental implants, poorly fitting dentures, chemotherapy, corticosteroids, poor oral hygiene, and diabetes.

A dental examination with appropriate preventive dentistry should be completed before starting romosozumab in patients with risk factors. Elective invasive dental procedures should be avoided during the treatment course if possible.

Atypical Femoral Fracture (AFF)

Atypical femoral fractures, occurring below the lesser trochanter or along the femoral diaphysis with minimal trauma, have been reported with romosozumab. [2] Unlike with bisphosphonates, where long-term suppression of bone remodeling is the proposed mechanism, the number of confirmed AFF cases with romosozumab remains small given its 12-month treatment cap.

Patients who develop thigh pain, groin pain, or hip pain during treatment should be evaluated with bilateral femoral radiographs. The fracture pattern is characteristic: a transverse lucent line in the lateral cortex, sometimes called the "dreaded black line."

Rebound Bone Loss: The Central Discontinuation Problem

This is the core discontinuation concern with romosozumab, and it deserves detailed examination. Unlike drugs where physical dependence drives withdrawal symptoms, romosozumab's discontinuation effect is a pharmacodynamic rebound, the bone resorption that was suppressed during treatment reasserts itself once the drug clears.

What the Data Show

In the FRAME extension, patients who completed 12 months of romosozumab and then received no further therapy (placebo in the extension) lost approximately 50% of their lumbar spine BMD gain within 12 months of stopping, with total hip BMD returning nearly to baseline. [4] Bone turnover markers, particularly C-terminal telopeptide (CTX, a resorption marker), rebounded sharply within 3 months of the last dose.

By contrast, patients who transitioned to denosumab (60 mg every 6 months) after romosozumab continued to gain BMD at the lumbar spine and total hip through 24 months of follow-up. [4]

Time Course of BMD Loss After Stopping

In the FRAME extension data, lumbar spine BMD peaked at month 12 (end of romosozumab) and declined measurably by month 18, with losses accelerating through month 24 in patients not given antiresorptive therapy. [4] The rate of BMD loss after romosozumab discontinuation may exceed the rate seen after stopping denosumab in some anatomical sites, though direct head-to-head comparisons are limited.

Fracture Risk Implications

The ARCH trial's fracture endpoints cover the romosozumab-then-alendronate sequence, and the data show durable fracture reduction. However, no large randomized trial has specifically tracked fracture rates in patients who stop romosozumab without follow-on therapy. Observational data and mechanistic reasoning both support the conclusion that fracture risk returns toward pre-treatment levels rapidly without a follow-on drug.

Sequential Therapy Decision Framework

The following approach reflects current AACE and Endocrine Society guidance, combined with the FRAME and ARCH trial sequencing data:

1. Month 12 (last romosozumab dose): Order DXA and bone turnover markers (P1NP and CTX) within 30 days.
2. Transition within 30 days: Start an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) or, for patients at very high fracture risk, denosumab 60 mg SC every 6 months.
3. Prefer denosumab when the patient had a prior vertebral fracture, T-score below minus 3.0, or a suboptimal BMD response to romosozumab (defined as <3% lumbar spine gain).
4. Do not sequence to denosumab and then stop denosumab without a bisphosphonate bridge, as denosumab discontinuation carries its own rapid rebound fracture risk.
5. Reassess at month 24 post-romosozumab with repeat DXA to confirm BMD is stable or improving on the follow-on therapy.

Arthralgia and Musculoskeletal Pain

Arthralgia was reported in approximately 12.6% of romosozumab-treated patients vs. 11.5% of placebo in FRAME, a modest but consistent difference. [4] Headache was also numerically more common with romosozumab (4.9% vs. 4.0%).

These are not discontinuation symptoms in the pharmacologic sense. They occur during treatment rather than after stopping. Persistent or severe joint pain should prompt evaluation to rule out inflammatory arthritis, as rare cases of drug-induced inflammatory arthropathy have been reported with biologic agents broadly.

Anti-Drug Antibodies and Immunogenicity

Approximately 18% of romosozumab-treated patients in clinical trials developed anti-romosozumab antibodies, and roughly 4% had neutralizing antibodies. [2] The clinical significance appears limited: neutralizing antibody status did not correlate with reduced BMD response or increased adverse events in FRAME or ARCH. No hypersensitivity reactions attributable to immunogenicity were confirmed in trial data, though FAERS includes scattered post-market reports of infusion-like reactions.

FAERS and Post-Market Surveillance Through 2024

The FDA Adverse Event Reporting System (FAERS) data through 2024 confirm the label-identified risk profile without adding unexpected new signals. The most frequent MedDRA preferred terms in voluntary reports include:

• Injection-site pain and erythema
• Arthralgia and myalgia
• Cardiovascular events (MI, stroke), consistent with the boxed warning
• ONJ, particularly in patients with concurrent dental procedures
• Hypocalcemia in renally impaired patients

No new organ-system signals have emerged from FAERS that would change current prescribing guidance. The signal-to-noise ratio in spontaneous reporting systems is inherently limited, and these data support rather than replace the controlled trial evidence.

Special Populations: Cardiovascular Disease, Renal Impairment, and Prior Fracture

Patients With Prior Cardiovascular Disease

Romosozumab is contraindicated, per label, in patients who have had an MI or stroke within the preceding 12 months. [2] For patients with stable coronary artery disease, prior revascularization, or risk factors such as hypertension and dyslipidemia, the prescribing decision requires weighing fracture risk (which is itself a mortality risk in older women) against cardiovascular exposure over 12 months.

The AACE 2020 guidelines state: "Romosozumab should not be used in patients who have had a myocardial infarction or stroke within the preceding year and should be used with caution in patients with other cardiovascular risk factors." [5]

Renal Impairment

No dose adjustment is required for patients with renal impairment, including those with severe impairment (eGFR <30 mL/min/1.73 m²). However, these patients are at higher risk for hypocalcemia and require close monitoring of serum calcium, phosphate, and PTH at baseline and throughout therapy. [2] Romosozumab has not been studied in patients on dialysis.

Patients With Recent Fracture

Women with a recent clinical fracture represent the population deriving the greatest absolute benefit from romosozumab. In ARCH, the number needed to treat to prevent one vertebral fracture over 24 months (12 months romosozumab plus 12 months alendronate) was approximately 11 in the high-risk subgroup. [3] This high absolute benefit may justify romosozumab even in patients with borderline cardiovascular risk, but the decision requires a documented shared decision-making conversation.

Drug Interactions and Combination Therapy

No formal pharmacokinetic drug-drug interaction studies with romosozumab have been published, reflecting its mechanism as a monoclonal antibody metabolized via proteolytic pathways rather than cytochrome P450. Combining romosozumab with antiresorptive agents concurrently (rather than sequentially) has been studied in small trials. The FRAME trial's denosumab arm showed that denosumab given after romosozumab was superior to placebo after romosozumab, but simultaneous combination therapy is not FDA-approved and adds cardiovascular exposure without established additional efficacy.

Calcium and vitamin D supplementation are not optional adjuncts during romosozumab therapy. They are part of the standard treatment package. Most clinical trials required patients to take 500 to 1,000 mg elemental calcium plus 600 to 800 IU vitamin D daily.

Monitoring Checklist During and After Romosozumab

A structured monitoring schedule reduces the risk of serious adverse events and missed discontinuation planning:

Before first dose:

• Serum calcium and 25-OH vitamin D (correct deficiencies)
• Blood pressure and cardiovascular risk assessment
• Dental examination in high-risk patients
• Baseline DXA with vertebral fracture assessment

During the 12-month course (each visit):

• Review for chest pain, dyspnea, or neurologic symptoms (cardiovascular screening)
• Injection-site assessment
• Calcium supplementation adherence check
• Month 6: optional bone turnover markers (P1NP) to confirm anabolic response

At month 12 (last dose):

• Repeat DXA within 30 days
• Bone turnover markers (P1NP and CTX)
• Prescribe follow-on antiresorptive before leaving the clinic
• Document cardiovascular event-free status over the 12-month course